Is Gennex Lab. overvalued or undervalued?

As of 3 November 2025, Gennex Lab. has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 21.32, an EV to EBITDA of 14.90, and a PEG ratio of 1.62. In comparison to its peers, Gennex Lab. shows a more favorable valuation against Sun Pharma, which has a PE ratio of 35.62, and Divi's Lab, which has a PE ratio of 78.12, indicating that Gennex Lab. is priced more competitively within the industry.
Despite recent stock performance showing a decline of 5.44% over the past week and a year-to-date drop of 5.39%, the company's long-term return of 150.97% over three years highlights its potential for growth. With a return on capital employed (ROCE) of 11.96% and a return on equity (ROE) of 9.02%, Gennex Lab. is positioned well for future performance, reinforcing its undervalued status in the current market.